Nifluril Adultes (Morniflumate)

Morniflumate works by reversibly inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, which are essential for the conversion of arachidonic acid into prostaglandins. By lowering prostaglandin production, the drug diminishes inflammation, pain signalling and fever responses at the site of tissue injury, resulting in an overall anti‑inflammatory and analgesic effect.

The appropriate dose of Nifluril Adultes is determined by the prescribing healthcare professional based on the patient’s specific condition, severity of symptoms, age, renal and hepatic function, and any concomitant medications. Patients should follow the prescriber’s instructions and not alter the dose without medical guidance.

Safety data for Morniflumate during pregnancy and lactation are limited. Because NSAIDs can affect fetal renal development and may be excreted in breast milk, the drug should be used only if the potential benefit justifies the potential risk. Pregnant or nursing women should discuss alternatives with their healthcare provider.

To request Nifluril Adultes, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements) and the necessary import documentation.

Morniflumate belongs to the fenamate subclass of NSAIDs, which generally offers a broader COX inhibition profile compared with COX‑2‑selective agents. Compared with traditional NSAIDs such as ibuprofen or diclofenac, fenamates may provide comparable analgesia but can carry a higher risk of gastrointestinal irritation. Choice of therapy should consider efficacy, safety profile, patient comorbidities and physician experience.

Nifluril Adultes should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture, heat and direct sunlight. The rectal dosage form must be kept dry and sealed until use. Do not freeze the product, and keep it out of reach of children.

Nifluril Adultes is supplied as a rectal preparation intended for insertion into the rectum, where it releases Morniflumate locally. Administration should follow the prescriber’s instructions regarding the amount to be inserted, the frequency of dosing, and any required positioning to ensure optimal absorption. Hand hygiene and proper insertion technique are essential.

Serious adverse events associated with Morniflumate include gastrointestinal ulceration or bleeding, severe hepatic injury, acute renal failure, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and anaphylaxis. Patients should be instructed to seek immediate medical attention if they experience symptoms such as black stools, jaundice, sudden swelling, rash, or difficulty breathing.

Nifluril Adultes should be avoided in individuals with a known hypersensitivity to Morniflumate or any other NSAID, those with active gastrointestinal ulceration or bleeding, severe hepatic or renal impairment, and patients receiving anticoagulant therapy where bleeding risk is high. It is also contraindicated in patients with a history of severe cardiovascular events unless specifically advised by a physician.